Now, 4 scientists with the NIH claim they hold partial patent rights on that vaccine and stand to make up to $150,000 per year.  Meanwhile, as Moderna's stock price continues to soar, 5 top executives have sold off $89 million dollars worth of shares, even as the company continues to bypass standard vaccine protocols in the development of its C0-vId v@ccine